Ignite Creation Date:
2024-05-06 @ 7:26 PM
Last Modification Date:
2024-10-26 @ 3:07 PM
Study NCT ID:
NCT06012448
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2023-10-05
First Post:
2023-08-21
Brief Title:
The Immunologic Effects of Dupilumab in the Treatment of Dermal Hypersensitivity Reaction
Sponsor:
University of Michigan
Organization:
University of Michigan
Study Overview
Official Title:
The Immunologic Effects of Dupilumab in the Treatment of Dermal Hypersensitivity Reaction
Status:
ACTIVE_NOT_RECRUITING
Status Verified Date:
2024-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This research is studying a drug called dupilumab to learn about its safety and its effect as a treatment for participants with dermal hypersensitivity reaction This study will help better understand why and how dermal hypersensitivity reaction occurs and how dupilumab might help treat this condition
Detailed Description:
Dermal hypersensitivity reaction is a skin rash that can happen as a reaction to a known trigger or it can happen for unknown reasons Not a lot is known about why the rash occurs and what happens to the immune system to cause this rash Dupilumab a biologic drug that is given as an injection under the skin may treat dermal hypersensitivity reaction This study tries to better understand dermal hypersensitivity reaction and how the immune system responds to dupilumab
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
False
Is an FDA AA801 Violation?:
None